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This study aimed to define the maximum-tolerated dose (MTD) of fixed dose rate (FDR) of gemcitabine (20-20-difluorodeoxycitidine)
infusion with circulating haemopoietic progenitor support and to evaluate the activity of the treatment. Secondary end points were
pharmacokinetic of gemcitabine and difluorodeoxyuridina (dFdU) measured at first course and the activity andexpression profile of
cytidine deaminase (CdA) on circulating mononuclear cells. Patients with advanced pancreatic carcinoma received escalating dose of
gemcitabine 10mgm
 2min
 1 every 2 weeks with circulating haemopoietic progenitor support. First dose level was 3000mgm
 2
and the doses were increased by 500mgm
 2 until MTD. In all, 23 patients were enrolled. Toxicities were mild or moderate; the only
patient treated at 7000mgm
 2 died because of toxicity; therefore; the MTD was established at 6500mgm
 2. The overall response
rate was 22.2%. The AUC of gemcitabine showed a dose-dependent increase, while the AUC of dFdU reached a plateau at
4500mgm
 2. A significant relationship was found between the AUC of dFdU and CdA expression and activity (Po0.05). Moreover,
progression rate and survival were significantly related to CdA expression and activity levels. The activity of high-dose gemcitabine is
not superior to that reported with less intensive FDR schedules. The predictive role of CdA expression and activity on outcome
deserves further investigation.
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Pancreatic carcinoma is the fifth most common cause of cancer
death in Western countries. At diagnosis, the majority of patients
have locally advanced unresectable or metastatic disease for which
there is no curative therapy (Evans et al, 1997, p 1054). For many
years, 5-fluorouracil has been considered the standard treatment of
pancreatic cancer with response rates ranging from 0 to 19% (Palmer
et al, 1994). More recently, gemcitabine (20-20-difluorodeoxy-
citidine) has proven activity against a variety of solid tumours
including pancreatic cancer (Huang et al, 1991; Rothenberg et al,
1996). A weekly short time (30min) intravenous (i.v.) infusion of
1000mgm
 2 is the recommended dose and schedule. However,
even if effective, this schedule might not to be the optimal one
taking into account the metabolism of the drug.
Gemcitabine is a prodrug that is initially phosphorylated by
deoxycytidine kinase (dCK) to gemcitabine monophosphate and
subsequently to gemcitabine diphosphate and gemcitabine triphos-
phate. Incorporation of gemcitabine triphosphate into DNA
inhibits replication with induction of apoptosis. Phosphorylation
of gemcitabine to the monophosphate by deoxycytidine kinase
is the rate-limiting step in the accumulation of the active
diphosphate and triphosphate metabolites. Grunewald et al and
Abbruzzese et al have demonstrated that the ability of mono-
nuclear cells to accumulate gemcitabine triphosphate during
therapy was saturable and the optimal plasma concentration of
gemcitabine that maximised the rate of formation of gemcitabine
triphosphate was approximately 20mmoll
 1 (Grunewald et al,
1990, 1991). In these studies, this target plasma gemcitabine
concentration and the optimal intracellular accumulation of
gemcitabine triphosphate was achieved with dose rates of
10mgm
 2min
 1 (Abruzzese et al, 1991; Grunewald et al, 1992).
Based on these data, a number of phase I trials have explored the
possibility to prolong the duration of infusion time; other trials
escalated both the dose and infusion duration using a fixed dose
rate (FDR) of 10mgm
 2min
 1 (Abbruzzese et al, 1991; Grunewald
et al, 1992; Poplin et al, 1992; Pollera et al, 1997). Tempero et al
have compared in a phase II randomised trial the standard
gemcitabine infusion in 30min infusion vs an FDR infusion of
10mgm
 2min
 1 in pancreatic carcinoma. A significant increase
in response rate, a longer median survival and a higher 1-year
survival rate was reported in the FDR infusion-treated patients.
However, patients receiving the FDR infusion experienced
consistently more haematologic toxicity and cumulative myelo-
suppression was reported (Tempero et al, 2003).
On the basis of these data from this trial and preclinical data
suggesting a dose–response relationship (Csoka et al, 1995; Von
Hoff, 1996), we have designed a dose-finding phase I trial of
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sgemcitabine given as prolonged FDR (10mgm
 2min
 1) infusion
every 14 days with haemopoietic progenitor support in patients
with advanced pancreatic adenocarcinoma.
End points of the study were to define the maximum-tolerated
dose (MTD) of prolonged FDR of gemcitabine plus progenitor
blood cells and to evaluate the activity of the treatment in terms of
objective responses. Additive end points of the trial were to study
the plasma pharmacokinetic of gemcitabine and its metabolite
difluorodeoxyuridina (dFdU) following FDR infusion and to
evaluate the influence of gene expression and activity of cytidine
deaminase (CdA) on clinical outcome.
MATERIALS AND METHODS
Eligibility
Patients p75 years old, performance status 0–1 (ECOG scale) with
histologically confirmed unresectable advanced or metastatic
pancreatic carcinoma were eligible for the study. Other eligibility
criteria were bidimensionally measurable disease, leucocyte count
X3.5 10
9l
 1, platelet count X100 10
3l
 1, haemoglobin level
X10gl
 1, no active infection, no severe concurrent medical
condition and no previous treatment for the advanced disease.
Prior adjuvant chemotherapy and/or radiotherapy was permitted.
The patients were required to sign an informed consent and the
Ethics Committee of St Chiara University Hospital approved the
study.
Treatment plan
Granulocyte-colony-stimulating factor (G-CSF) 10mgkg
 1day
 1
subcutaneously (s.c.) was administered for 5 days to mobilise
circulating haemopoietic progenitor cells. When the peripheral
blood absolute CD34þ cell count was X50ml
 1, the aphaeresis
procedure was performed using a Fenwall CS 3000 cell separator
(Baxter, Chicago, IL, USA). Whole blood (8–10l) was processed
per procedure using continuous flow blood at a flow rate of
50mlmin
 1. A minimum of 12 10
6 CD34þ cellkg
 1 were
collected from each patient.
Gemcitabine was administered at an FDR of 10mgm
 2min
 1 at
the starting dose of 3000mgm
 2 (starting time infusion 300min).
If no dose-limiting toxicity occurred in the first two courses, the
dose of gemcitabine was escalated by 500mgm
 2 in cohorts of
three patients until maximum tolerable dose. In the absence of
toxicity or progression, the courses were repeated every 14 days
for a maximum of 12 courses. Peripheral blood progenitors were
reinfused 24h after each course of chemotherapy. At the time of
reinfusion, frozen PBPC were thawed rapidly in a 371C warm bath
and reinfused through a central venous catheter: at least 0.5 10
6
CD34þ cellkg
 1 were reinfused per course. Following PBPC
infusion, G-CSF 5mgkg
 1day
 1 s.c. was administered starting day
þ5 to day þ7.
Safety and activity assessment
A complete restaging of disease was performed after four, eight
and 12 courses of treatment. Definition of response and toxicity
were based on WHO criteria. Dose-limiting toxicity of gemcitabine
was defined by one of the following criteria: G3 stomatitis lasting
more than 5 days, G4 stomatitis and impossibility to recycle on day
14 in more than 40% of the courses. The MTD of gemcitabine was
considered the dose level immediately below that producing one
DLT out of three patients.
Pharmacokinetic analysis
Blood samples (4ml each) were drawn at the first cycle of
gemcitabine administration from an i.v. cannula placed in an
antecubital vein before drug administration, after 30min and every
3h during infusion and 5, 15, 30, 45min and 1, 3, 9, 15 and 24h
after the end of treatment and collected in heparinised test tubes
containing 10mM tetrahydrouridine (Calbiochem, San Diego, CA,
USA) to inhibit gemcitabine metabolism by CdA. Plasma was
obtained by centrifugation at 5000g for 10min, split in aliquots
and stored at  801C.
Plasma levels of gemcitabine and its metabolite 20,2 0-difluoro-
deoxyuridine (dFdU) were determined by a previously des-
cribed reverse-phase high-performance liquid chromatography
with ultraviolet detection (HPLC-UV) method optimised for the
present study (Wang et al, 2003). Drug extraction was performed
by adding 80ml of buffer (0.1moll
 1 Tris-HCl, 50mmoll
 1 b-
mercaptoethanol, pH 8.0) and 50ml of 40% (wv
 1) trichloroacetic
acid (TCA) to 120ml of plasma. Samples were kept on ice for
20min and proteins were precipitated by centrifugation for 10min
at 10000g. Supernatants were neutralised with 500ml trioctyla-
mine:1,1,2-trichloro-trifluoroethane (1:4), centrifuged for 1min
at 10000g and 50ml were injected onto a Simmetry Shield C18
5mm, 300 4.6mm column (Waters, Milford, MA, USA) eluted at
a flow rate of 1mlmin
 1 with 9% methanol, 6% acetonitrile and
heptane sulphonic acid 5mM, pH 3.1. The chromatographic
apparatus was a Waters LC Module I plus equipped with a WISP
416 autosampler and a variable wavelength UV detector (Waters)
set at 270nm for peak detection. Calculation of gemcitabine and
dFdU concentration in samples was performed against calibration
curves in the range of 0.3–300mmoll
 1 in the plasma of healthy
donors. Maximum plasma concentration (Cmax, mmoll
 1)o f
gemcitabine and dFdU were determined from visual inspection
of the plasma concentration–time curves, while the area under the
plasma concentration–time curve (AUC, min mmoll
 1) was
calculated with the linear trapezoidal rule.
Pharmacogenomic analysis
Analysis of CdA enzyme activity Mononuclear cells were
obtained by density-gradient centrifugation of patients’ blood
samples (14ml), obtained before drug administration, on Ficoll–
Hypaque (density 1.077gl
 1, Pharmacia, Uppsala, Sweden). Cells
were resuspended at 3 10
6 cells100ml
 1 of buffer (0.1moll
 1
Tris-HCl, 50mmoll
 1 b-mercaptoethanol, pH 8.0 (van Haperen
et al, 1996). The suspension was sonicated and centrifuged for
20min at 10000g to obtain crude cytoplasmatic extracts and 10ml
of 0.5mmoll
 1 gemcitabine was added to 50ml of supernatant and
40ml of buffer. Reaction mixture was incubated for 30min at 371C
and extraction of analytes was obtained with 25ml 40% TCA.
Samples were kept on ice for 20min, neutralised with 250ml
tryoctylamine:1,1,2-trichloro-trifluoroethane (1:4) and centri-
fuged for 5min at 10000g. The upper layer was removed and
analytes were separated by HPLC, as described above in
‘Pharamacokinetic analysis’. Human mononuclear cells from blood
donors were the source of cytoplasmatic extracts to be used as a
calibrate matrix and spiked with dFdU to generate calibration
curves, in the range of 33–1000mmoll
 1. The HPLC method was
linear (R
240.995) for plasma and cytoplasmatic extracts over the
analytical range and the limit of quantitation corresponded to the
lower limit of the calibration curves. Intraday variability was
4 2.5 and o12% over the full analytical range of calibration
standards, while interday variability was 4 1.5 and o15%.
Concentrations of dFdU were normalised for cytoplasm protein
concentration, which was measured with the Lowry reagent
(Sigma, St Louis, MO, USA).
PCR analysis of CdA gene expression Total RNA was extracted
using the TRI REAGENT LS (Sigma, St Louis, MO, USA) and
dissolved in RNAse-free water containing 10mmoll
 1 dithiothrei-
tol and 200Uml
 1 RNase inhibitor (Gibco, Gaithersburg, MD,
USA). RNA (1mg) was reverse transcribed at 371C for 1h in 100-ml
reaction volume containing 0.8mM dNTPs (Sigma, St Louis, MO,
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of RNase inhibitor and 0.05mgml
 1 of random primers. The cDNA
was amplified by quantitative, real-time PCR with the Applied
Biosystems 7900HT sequence detection system (Applied Biosys-
tems, Foster City, CA, USA). PCR reactions were performed in
triplicate using 5ml of cDNA, 12.5ml of TaqMan Universal PCR
Master Mix (Applied Biosystems), 2.5ml of probe and 2.5mlo f
forward and reverse primers in a final volume of 25ml. Forward (F)
and reverse (R) primers and probe (P) were designed with Primer
Express 2.0 (Applied Biosystems) on the basis of CdA gene
sequence: 50-TCAAAGGGTGCAACATAGAAAATG-30 (F), 50-CGG
TCCGTTCAGCACAGAT-30 (R) and 50-CTGCTACCCGCTGGG-30
(P) (Demontis et al, 1998). PCR thermal cycling conditions and
optimisation of primer concentrations were reported in detail by
Giovannetti et al (2004). The amount of target gene, normalised to
GAPDH and relative to the calibrator (mononuclear cells from
volunteer blood donors), is given as 2 DDCT.
Statistics
Data were expressed as mean values7s.d. and the Pearson/
Spearman correlation test and regression analysis were used to
demonstrate the relationship between CdA expression, enzyme
activity and dFdU AUC. Correlation between response rate and
CdA expression and activity level was performed using w
2 test.
Overall survival (OS) curves were calculated from the date of
diagnosis until the date of death or last follow-up examination
according to the Kaplan–Meier method and compared by the log-
rank test. Variables studied in univariate analysis included CdA
expression and activity levels, dFdU AUC, age, sex and drug dose
levels. Differences were considered significant if the Po0.05.
RESULTS
Characteristics of the patients
In all, 25 patients with locally advanced or metastatic pancreatic
carcinoma entered into this the study. Two patients were unable to
receive the planned treatment due to poor mobilisation of
peripheral blood progenitors. A total of 23 patients collected the
minimum number of CD34þ cells to support at least one course
of treatment. The median age was 56 years (range 42–75 years)
and median performance status (WHO scale) was 0 (range 0–1).
Three patients had locally advanced disease, 20 had metastatic
disease: two patients had received previous adjuvant chemotherapy
with gemcitabine as single agent. Predominant metastatic site
was the liver in 14 patients (60.9%) (Table 1). The median number
of aphaeresis procedure per patients was 3 (range 2–7) and
median number of CD34þ cellkg
 1 collected per aphaeresis was
2.23 10
6 (range 0.15–10.1). Owing to the poor collection after
G-CSF only, 15 patients underwent a further mobilisation with
gemcitabineþG-CSF. The average of CD34þ cellkg
 1 collected
per aphaeresis after G-CSF and after gemcitabineþG-CSF was
2.18 10
6 (s.d.71.65 10
6) and 4.12 10
6 (s.d.72.46 10
6),
respectively. The difference was statistically significant
(P¼0.0001).
Toxicity
Three patients were treated for each dose level from 1st
(3000mgm
 2 in 300min) to 6th (6000mgm
 2 in 600min), four
patients at 7th dose level (6500mgm
 2 in 650min) and one patient
at 8th dose level. A total of 137 courses were administered and
were evaluable for toxicity. In all, 15 courses were administered at
1st level, 19 at 2nd, 16 at 3rd, 15 at 4th, 32 at 5th, 27 at 6th, 13 at 7th
and 1 at 8th. G3–4 nonfebrile neutropenia occurred in 2.8% of
courses, G3 anaemia in 6.5% of courses and G3 thrombocytopenia
in 1.5% of courses. The patient treated at 7000mgm
 2 experienced
a G4 mucositis and died 25 days after the first course of treatment.
Mucositis was considered the dose-limiting toxicity and
6500mgm
 2 was defined as the MTD. Other haematologic and
nonhaematologic toxicities were mild or moderate: G2 fever was
reported in 11.6% of courses, G1 dermatitis in 6.4% and G1 deep
venous thrombosis in 2.9% (Table 2).
Outcome
In all, 18 patients completed at least four courses of treatment and
are evaluable for response. Four patients (22.2%) achieved an
objective response: one patient achieved a complete remission
lasting 21þ months and three patients achieved a partial
remission; seven patients (36.8%) had a stable disease. Seven
patients experienced early progression. Five patients received less
than four courses of chemotherapy due to refusal (two patients)
and DVT (three patients). According to the intention-to-treat
analysis, median time to progression was 4.8 months (95% CI 1.7–
7.9) and median OS was 7.0 months (95% CI 4.9–9.1); the 1-year
survival rate was 21.9%. (Figure 1).
Pharmacokinetic analysis The plasma concentration of gemcita-
bine reached the target concentration of 15mmoll
 1 within 30min
from the start of infusion and remained above this threshold level
during the infusion period. The maximum plasma concentration
(Cmax) of gemcitabine was achieved at the end of the infusion
and ranged from 24.8473.93 to 84.36715.97mmoll
 1, suggesting
that there was heterogeneity in the plasma kinetics among the
patients, whereas the AUC ranged from 5588.7271447.85
to 33402.9573136.62min mmoll
 1, showing a dose-dependent
increase. Gemcitabine rapidly disappeared from plasma, and
30min after the end of drug infusion, only the metabolite dFdU
was detectable. Cmax of dFdU ranged from 77.5178.70 to
144.431727.79mmoll
 1 and was achieved approximately 15min
after the end of gemcitabine infusion. The AUC ranged
from 36668.7673153.76 to 51314.0878958.63min mmoll
 1,
corresponding to the 3000–4500mgm
 2 dose levels; over the
Table 1 Patient characteristics (range)
No. of patients 23
M/F 13/10
Median age (years) 56 (42–75)
Median ECOG PS 0 (0–1)
Locally advanced disease (no. of pts.) 3
Metastatic disease (no. of pts.) 20
Previous adjuvant CT (no. of pts.) 2
Median no. of aphaeresis/pt. 3 (2–7)
Median CD34+ cellskg
 1/aphaeresis 2.23 10
6 (0.15–10.1)
G-CSF 1.79 10
6 (0.15–9.12)
Gemcitabine+G-CSF 3.61 10
6 (0.89–10.1)
No. of total courses 137
ECOG PS¼Eastern Cooperative Oncology Group Performance Status; G-
CSF¼granulocyte-colony-stimulating factor.
Table 2 Toxicities (WHO scale) 137 courses
G1 (%) G2 (%) G3 (%) G4 (%)
Anaemia 24 (17.5) 16 (11.6) 9 (6.5) —
Neutropenia 2 (1.4) 6 (4.3) 2 (1.4) 2 (1.4)
Thrombocytopenia 3 (4.4) 2 (2.9) 1 (1.5) —
Diarrhoea — 2 (2.9) — —
Fever — 16 (11.6) — —
Dermatitis 5 (3.6) — —
WHO¼World Health Organization.
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 2 dose, the AUC of the metabolite did not increase,
possibly depending on saturable metabolism (Table 3).
Correlation between CdA gene expression, enzyme activity and
dFdU pharmacokinetics CdA gene expression in mononuclear
cells from patients showed a 57-fold variation among patients,
ranging from 0.56 to 31.67; in addition, the enzymatic activity
varied from 0.32 to 4.78nmolmin
 1mg
 1 protein. A significant
relationship was found between CdA expression and activity
(R
2¼0.72, Po0.001), as well as between the plasma AUC of dFdU
and CdA expression and its activity (Po0.05) (Figure 2).
Relationship between CdA expression, CdA activity and clinical
outcome The analysis of CdA expression and activity was
performed on 17 patients and 16 of these are evaluable for
response. Patients with mononuclear cells’ CdA expression level
o10U and CdA activity level o2nmolmin
 1mg
 1 protein
achieved an objective response (one CR, three PR) or a stable
disease (six patients). On the contrary, patients with CdA
expression level 410U and CdA activity level
42nmolmin
 1mg
 1 protein showed an early progression of
disease (six patients): the differences are statistically significant
with Po0.05. In a univariate analysis, patients whose mononuclear
cells had CdA expression levels 410 (seven patients, median
survival time, 3.65 months, 95% CI 3.31–3.98) had significantly
(P¼0.03) shorter OS than patients with CdA expression levels
o10 (10 patients, median survival time, 8.51 months, 95% CI
6.01–11.00) (Figure 3). Similar results were obtained with CdA
activity analysis; patients whose mononuclear cells had CdA
activity levels 42nmolmin
 1mg
 1 protein (nine patients, median
survival time, 3.98 months, 95% CI 3.02–4.93) had significantly
(P¼0.006) shorter OS than patients with CdA activity levels
o2nmolmin
 1mg
 1 protein (eight patients, median survival
time, 8.74 months, 95% CI 3.46–14.02) (Figure 4). In contrast,
no significant impact on OS was found both for dFdU AUC
o40.000min mmoll
 1 and for dose level 44500mgm
 2. Finally,
among the other parameters studied, male sex was associated with
shorter survival (median survival time, 5.22 months, 95% CI 1.75–
8.70, vs 10.02 months, 95% CI 3.20–16.84, P¼0.04), while no
significant impact on OS was found for age (o56 years).
DISCUSSION
The MTD of gemcitabine is strongly associated to the infusion
schedule: when administered daily for 5 days over 30min, the
MTD was reached at 9mgm
 2day
 1 (O’Rourke et al, 1994); on
the other hand, when the drug was administered biweekly, the
MTD was observed at 4000mgm
 2day
 1 (Brown et al, 1991). In
the pivotal trial conducted by Burris et al (1997), gemcitabine
produced a response rate of 5.4%, a median survival time of 5.7
months and the clinical benefit response in 23.8% of the patients.
In this trial, gemcitabine was administered on a weekly basis as
a 30-min infusion and this schedule has become the standard
modality of administration. In a phase I trial, when gemcitabine
was administered at FDR to patients with previously treated solid
tumours including pancreatic cancer, the MTDs were 1500mgm
 2
over 150min (Brand et al, 1997) and 1800mgm
 2 over 180min
weekly for 3 weeks (Touroutoglou et al, 1998). Preclinical and
clinical data suggest that an infusion rate of 10mgm
 2min
 1 may
be more effective even if myelotoxicity can become the dose-
limiting toxicity (Veerman et al, 1996; Tempero et al, 2003). An
FDR of 10mgm
 2min
 1 can provide plasma concentrations
(approximately 20mmoll
 1) that are sufficient to maximise the
rate of gemcitabine triphosphate accumulation. Two phase I trials
have shown that a single course of gemcitabine as FDR infusion of
10mgm
 2min
 1 for 12h can be safely administered alone or in
combination with mitoxantrone in patients with relapsed/refrac-
tory acute leukaemia (Gandhi et al, 2002; Rizzieri et al, 2002).
The data of our study demonstrate that multiple courses of
gemcitabine can be administered at the FDR of 10mgm
 2min
 1
up to 11h every 14 days with peripheral blood stem cell support.
Tolerability was excellent with a G4 neutropenia observed in 1.4%
of the courses only, while other haematological and clinical
toxicities were pgrade 3. All the courses were administered at the
scheduled 2-week interval. Surprisingly, the first patient treated at
the dose level of 7000mgm
 2 developed a severe mucositis and
died at day 25 after the first course. It was therefore decided to stop
the dose escalation in spite of excellent tolerability experienced by
all other patients.
Unfortunately, the activity of this intensive treatment was lower
than expected: an objective response was observed in 22.2% of
patients, while a disease control (ORþs.d.) was achieved in 61% of
the patients; median TTP and OS were 4.8 and 7 months,
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Figure 1 Progression-free survival (PFS) and overall survival (OS) of 23
patients.
Table 3 Plasma pharmacokinetics of gemcitabine and dFdU
Gemcitabine DfdU
Dose (mgm
 2) Cmax (lmoll
 1) AUC (min lmoll
 1) Cmax (lmolml
 1) AUC (min lmoll
 1)
3000 24.8473.93 5588.7271447.85 77.5178.70 38026.64716537.09
3500 35.9875.52 7700.697530.94 108.5074.87 36879.9472704.15
4000 44.3976.34 11914.7871462.83 136.44717.32 51039.5072573.54
4500 58.04713.40 17100.9772650.02 144.43727.79 51314.0878958.63
5000 84.36715.97 28782.2774597.91 141.85757.59 35398.3475910.78
6000 76.5276.45 31119.0971971.54 109.613715.24 41235.61716601.49
6500 74.7776.93 33402.9573136.62 110.12714.62 36668.7673153.76
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are inferior to those reported by Tempero et al (2003) with
gemcitabine given at FDR of 1500mgm
 2 without peripheral
blood stem cell support.
In agreement with Tempero et al, the mean plasma gemcitabine
concentration at the end of an FDR infusion of 10mgm
 2min
 1
was lower than that of the standard 30-min infusion. Conversely,
Cmax of gemcitabine ranged from 24.8473.93 to
84.36715.97mmoll
 1, while in a standard 30-min infusion with
a dose level of 2000mgm
 2, the Cmax was 136.17749.50mmoll
 1
(De Pas et al, 2000). However, the FDR infusion was able to
generate sustained gemcitabine levels in plasma above the
threshold of 15mmoll
 1, which is higher than the concentration
required to achieve maximal intracellular accumulation of
gemcitabine triphosphate; moreover, the gemcitabine AUC showed
a dose-dependent increase. In contrast, the AUC of the gemcita-
bine metabolite showed a dose-dependent increase until the
4500mgm
 2 dose levels; above this dose level, the AUC did not
increase, possibly depending on saturable metabolism.
The data of the present study also demonstrate a genotype–
phenotype correlation between CdA gene expression, enzyme
activity and AUC of the metabolite dFdU produced by gemcitabine
deamination by CdA. These findings are in agreement with a
previous study by Schroeder et al that demonstrated a significant
correlation between the amount of CdA mRNA and enzyme
activity in leukaemic blasts, suggesting that variations in CdA
activity depends on differences in gene expression. Schroder et al
(1998) also showed a correlation of pretherapeutic CdA activity
with induction treatment response with the nucleoside analogue
cytarabine in patients with acute myeloid leukaemia. Kroep and
co-workers have recently shown a clear correlation between dCK
levels and gemcitabine sensitivity. In contrast to dCK, CDA activity
was not clearly related to gemcitabine sensitivity (Kroep et al,
2002).
In the present study, an univariate analysis demonstrated that
patients whose mononuclear cells had higher CdA expression and
activity levels had significantly higher rate of early progression and
shorter OS than patients with lower CdA expression and activity
levels, suggesting that gemcitabine metabolism in mononuclear
cells could predict clinical outcome. The small number of patients
in our study does not allow a multivariate analysis.
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Figure 2 Relation between CDA mRNA expression, enzymatic activity
and the AUC of dFdU.
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sIn conclusion, gemcitabine given as an FDR infusion of
10mgm
 2min
 1 in pancreatic cancer patients is feasible with
peripheral blood cell support up to 650min and the dose of
6500mgm
 2 is the MTD. No severe toxicities were observed at this
dose; however, the activity does not seem to be better than that
reported with other less intensive FDR schedules. Pharmacokinetic
data demonstrate a correlation between dose of gemcitabine and
its AUC; on the contrary, AUC of dFdU showed a plateau over
4500mgm
 2 of gemcitabine, possibly depending on saturable
metabolism. The observed relationship between CdA expression
and activity in mononuclear cells and treatment activity if
confirmed might be useful to discriminate patients at different
prognosis.
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